This test is performed to determine whether a patient’s red blood cells have been sensitized in vivo with immunoglobulin, complement, or both. The DAT is used most commonly to investigate possible hemolytic transfusion reactions, Hemolytic Disease of the Fetus and Newborn (HDFN), autoimmune hemolytic anemia, and drug-induced immune hemolysis. The clinical significance of a DAT result should take into consideration the patient's clinical history, diagnoses, and other laboratory test results.
Minimum of three (3) 6-7ml (lavender) tubes, unless pediatric patient, mixed thoroughly by gentle agitation.
Label specimen with the required minimum information: patient’s last name, first name, PHN or unique identifier and date of collection.
Complete Requisition (must include):
Patient’s last name, first name, date of birth and PHN or unique identifier
Facility name, complete address, phone and fax number